Development Reporting. BIOSANTE undertakes to provide PERMATEC regularly, but at least twice yearly (within sixty (60) days of the start of the calendar year and July 1, respectively), with an update reasonably detailing the steps and actions performed and results achieved or gained by BIOSANTE in pursuing the Development pursuant to the Development Plan, including without limitation information on the status of any filing for Approvals for each Product.
Appears in 5 contracts
Samples: License Agreement (Biosante Pharmaceuticals Inc), License Agreement, License Agreement (Antares Pharma Inc)
